Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
EUSA Pharma is a global biopharmaceutical company with a focus on oncology and rare diseases. The company is committed to developing and commercializing innovative treatments that can make a real difference to patients' lives. EUSA Pharma has a portfolio of specialized medicines and a pipeline of promising therapies, driven by a patient-centric approach. They strive to address unmet medical needs and improve outcomes for individuals affected by complex conditions worldwide. Since its acquisition in 2022, EUSA Pharma is part of the Recordati Group, enhancing its capabilities and global reach.
The UK headquarters serves as the central hub for EUSA Pharma's global operations, including strategic planning, corporate governance, research and development oversight, and international commercial coordination.
Located within Breakspear Park, a modern and well-equipped business park offering a professional environment with good amenities and transport links to London and international airports.
The work culture at EUSA Pharma's headquarters likely emphasizes collaboration, innovation, and a strong patient-first mindset, reflecting its mission in the biopharmaceutical sector. Employees are driven by the impact of their work on patients with serious diseases.
The headquarters' location in the UK is significant for its proximity to leading research institutions, regulatory bodies like the MHRA, and a skilled talent pool in the pharmaceutical industry. It facilitates collaboration and strategic partnerships within Europe and globally.
EUSA Pharma maintains a significant global presence with direct commercial operations in the United States and key European countries. Beyond these regions, the company extends its reach through a network of trusted distribution partners, making its specialized oncology and rare disease therapies available to patients in numerous international markets. Global functions supported include clinical development, regulatory affairs, medical affairs, supply chain management, and commercialization.
Breakspear Park, Breakspear Way
Hemel Hempstead
Hertfordshire
United Kingdom
Address: 111 North Congressional Lane, Suite 200, Langhorne, PA 19047, USA
To drive the commercialization and availability of EUSA Pharma's specialized treatments to patients in the U.S., engaging with healthcare professionals, regulatory authorities (FDA), and patient advocacy groups.
Address: Parc des Gaulnes, 355 Allée Jacques Monod, 69150 Décines-Charpieu, France
To manage and expand EUSA Pharma's presence in key European markets, ensuring patient access to its therapies and coordinating with national health authorities.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, EUSA Pharma' leadership includes:
EUSA Pharma has been backed by several prominent investors over the years, including:
Over the past year or so, EUSA Pharma experienced a significant leadership transition with the appointment of a new CEO. Other team adjustments may have occurred as part of strategic alignments following its acquisition by Recordati.
Discover the tools EUSA Pharma uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
EUSA Pharma likely uses standard professional email formats. Common patterns in the pharmaceutical industry include [first].[last]@domain.com or [firstinitial][last]@domain.com.
[first].[last]@eusapharma.com
Format
jane.doe@eusapharma.com
Example
80%
Success rate
Recordati Press Release • May 24, 2022
Recordati S.p.A. announced the completion of its acquisition of EUSA Pharma, a global specialty pharmaceutical company focused on rare diseases. This acquisition significantly strengthens Recordati's portfolio and presence in the rare disease market....more
EUSA Pharma Press Release • October 5, 2022
EUSA Pharma announced the appointment of Darrel P. Cohen, M.D., Ph.D., as its new Chief Executive Officer. Dr. Cohen brings a wealth of experience in the biopharmaceutical industry, particularly in oncology and rare diseases, to lead EUSA Pharma into its next chapter of growth....more
Recordati Full Year 2023 Results • February 27, 2024
Recordati's full-year 2023 financial results highlighted the positive contribution of EUSA Pharma's portfolio to its Rare Diseases segment. Products like QARZIBA® (dinutuximab beta) and Sylvant® (siltuximab) were noted for their performance, underscoring EUSA's strategic importance within the Recordati group....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including EUSA Pharma, are just a search away.